Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

NCT02183467 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2014-07-08

No results posted yet for this study

Summary

Assessment of the effect of BI 1356 or Placebo on prolongation of the QT interval

Conditions

  • Healthy

Interventions

DRUG

BI 1356, low dose

DRUG

BI 1356, high dose

DRUG

Placebo

DRUG

Moxifloxacin

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-06-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02183467 on ClinicalTrials.gov